Introduction: Our aim was to determine the expression ratios of MMP-2, MMP-9 and TIMP-2 in patients with RCC and study the correlation between the expression of tissue matrix metalloproteineases with their inhibitors and the clinicopathologic variables of the patients and evaluate the impact of these clinicopathologic variables on the prognosis. Materials and Methods: After exclusion of patients who received neoadjuvant therapies like embolization and/or immunotherapy, 72 patients (50 male, 22 female) with T1-3N0M0 clear cell pattern and minimum 2 years of follow-up who underwent radical nephrectomy for RCC between 1996 and 2004 were included in the study group. Cytoplasmic MMP-2, MMP-9 and TIMP-2 expressions were evaluated immunohistochemically with the percentage and intensity of the staining after pathologic evaluation. Results: The mean tumor size was 7.2 cm (2-22). Final pathology was T1N0M0, T2N0M0 and T3N0M0 in 51.4%, 38.9% and 9.7% of the patients, respectively. MMP-2, MMP-9 and TIMP-2 were positive in the 35%, 89% and 32% of the tumor cells, respectively. Clinical progression was detected in 11 (15.3%) patients in contrast to 61 (84.7%) of 72 patients who had no progression. We found a statistically significant positive correlation only between the clinic stage and TIMP-2 immunohistochemical staining score. Conclusion: Considering the complex and paradoxic interactions of MMP and TIMP, there may be other factors affecting the prognosis by a different mechanism other than these two protein groups.